StockMarketWire.com - Scancell Holdings has been granted a further extension to its option to licence the commercial use of Ichor Medical Systems' proprietary TriGrid electroporation delivery system with SCIB1, Scancell's ImmunoBody vaccine for the treatment of melanoma.

In exchange, Scancell has granted a partial waiver over the lock-up which prohibited the sale, during the two years following their issue, of ordinary shares in the Company ("Ordinary Shares") issued pursuant to exercise of the Tranche 2 share options (over 3,184,620 Ordinary Shares), issued as part payment for the licence option, as originally announced 16 July 2009 and extended in July 2014.

Subject to exercise of the Tranche 2 share options, Ichor will remain under an orderly market agreement requiring any sale of such Ordinary Shares during that two year period to be effected through Scancell's brokers.

Under the terms of the agreed extension, Scancell's licence option, which had been due to expire on 13 July 2016, has been extended until 13 July 2018.






Story provided by StockMarketWire.com